
CLAIMS:


1. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 2873), or a salt thereof.

2. The modified oligonucleotide of claim 1, which is the sodium salt or the potassium salt.

3. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 2873).

4. A pharmaceutical composition comprising the modified oligonucleotide of claim 1 and a pharmaceutically acceptable diluent.

5. The pharmaceutical composition of claim 4, wherein the pharmaceutically acceptable diluent is artificial cerebrospinal fluid.

6. The pharmaceutical composition of claim 5, wherein the pharmaceutical composition consists essentially of the modified oligonucleotide and artificial cerebrospinal fluid.

7. A pharmaceutical composition comprising the modified oligonucleotide of claim 3 and a pharmaceutically acceptable diluent.

8. The pharmaceutical composition of claim 7, wherein the pharmaceutically acceptable diluent is artificial cerebrospinal fluid.

9. The pharmaceutical composition of claim 8, wherein the pharmaceutical composition consists essentially of the modified oligonucleotide and artificial cerebrospinal fluid.

10. A compound comprising a modified oligonucleotide according to the following chemical notation: $A_{es}{}^{m}C_{eo}{}^{m}C_{eo}A_{eo}T_{eo}T_{ds}T_{ds}T_{ds}G_{ds}A_{ds}{}^{m}C_{ds}{}^{m}C_{ds}T_{ds}T_{ds}{}^{m}C_{ds}T_{eo}T_{eo}A_{es}G_{es}{}^{m}C_{e}$ (SEQ ID NO: 2873), wherein:

A = an adenine nucleobase,
mC = a 5-methyl cytosine nucleobase,
G = a guanine nucleobase,
T = a thymine nucleobase,
e = a 2'-$O(CH_2)_2OCH_3$ β-D-ribosyl sugar moiety,
d = a 2'-β-D-deoxyribosyl sugar moiety,
s = a phosphorothioate internucleoside linkage, and
o = a phosphodiester internucleoside linkage.

11. A pharmaceutical composition comprising the compound of claim 10, and a pharmaceutically acceptable diluent.

12. The pharmaceutical composition of claim 11, wherein the pharmaceutically acceptable diluent is artificial cerebrospinal fluid.

13. The pharmaceutical composition of claim 12, wherein the pharmaceutical composition consists essentially of the compound and artificial cerebrospinal fluid.

14. The compound of claim 10, comprising the modified oligonucleotide covalently linked to a conjugate group.

15. A pharmaceutical composition comprising the compound of claim 14, and a pharmaceutically acceptable diluent.

16. The pharmaceutical composition of claim 15, wherein the pharmaceutically acceptable diluent is artificial cerebrospinal fluid.

17. The pharmaceutical composition of claim 16, wherein the pharmaceutical composition consists essentially of the compound and artificial cerebrospinal fluid.